Skip to main content
Hubei Jumpcan Pharmaceutical Co., Ltd. logo

Hubei Jumpcan Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 600566 ISIN · CNE0000018X6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,935 across all filing types
Latest filing 2026-06-11 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600566

About Hubei Jumpcan Pharmaceutical Co., Ltd.

https://www.jumpcan.com/

Hubei Jumpcan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a diverse portfolio across therapeutic areas including pediatrics, digestive health, and respiratory care. It integrates traditional Chinese medicine with modern pharmaceutical science to produce a range of prescription and over-the-counter medications. Notable products include Pudilan Xiaoyan Oral Liquid, utilized for anti-inflammatory treatments, and Xiao'er Chixiao Tuishi Syrup, specifically formulated for pediatric use. The company operates advanced production facilities and emphasizes innovation in drug delivery systems and formulation technology. Its business model encompasses the entire value chain from raw material sourcing to clinical marketing, aiming to provide comprehensive health management solutions through a combination of traditional and chemical therapeutic options.

Recent filings

Filing Released Lang Actions
湖北济川药业股份有限公司关于完成工商变更登记及换发营业执照的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement that the company has completed the industrial and commercial registration procedures for a change in its registered capital and has obtained a new business license reflecting that change. It is not reporting financial results or calling a meeting, nor is it a management change, dividend notice, or AGM material. It specifically concerns a change in registered capital (share issue/capital change), matching the definition for SHA.
2026-06-11 Chinese
湖北济川药业股份有限公司关于合作产品玛硒洛沙韦片新适应症获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by Hubei Jichuan Pharmaceutical Co., Ltd. regarding the approval of a new indication for a collaborative drug product (“玛硒洛沙韦片”) by the National Medical Products Administration. It contains no financial statements or management/board changes, nor is it an earnings release, proxy statement, or details of transactions in shares. It is a standalone regulatory announcement of operational significance (drug registration certificate) and does not match any more specific category, so it falls under the general Regulatory Filings category (RNS).
2026-06-08 Chinese
湖北济川药业股份有限公司2026年员工持股计划第一次持有人会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the resolutions and vote results from the first holders’ meeting under the company’s 2026 employee stock ownership plan. It details the proposals considered, the voting outcomes (agree, oppose, abstain), and percentages. This aligns with “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-06-01 Chinese
湖北济川药业股份有限公司关于召开2025年年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 78% confidence The document is a formal stock exchange announcement by Hubei Jumpcan Pharmaceutical (600566) regarding the convening of a “2025 Annual and 2026 Q1 Results Briefing” (业绩说明会). It provides meeting time, location, participants, and Q&A logistics, but does not itself contain financial statements or operating results. It is therefore not an earnings release (ER) or the report itself (10-K/IR), nor an audit report or transcript. It aligns with an investor presentation event notice. Hence it should be classified as Investor Presentation (IP).
2026-05-27 Chinese
湖北济川药业股份有限公司关于2022年限制性股票与股票期权激励计划首次授予股票期权限制行权期间的提示性公告
Regulatory Filings Classification · 80% confidence The document is a regulatory announcement by Hubei Jichuan Pharmaceutical Co., Ltd. regarding restrictions on the exercise period of stock options under its 2022 incentive plan. It does not contain actual financial statements or constitute a full report, nor does it fit specialized categories like share issue capital changes (no new shares are being issued here) or insider transactions. Consequently, it falls under general regulatory filings for miscellaneous corporate announcements (RNS).
2026-05-27 Chinese
湖北济川药业股份有限公司关于2025年员工持股计划第一个锁定期届满的提示性公告
Share Issue/Capital Change Classification · 70% confidence The document is an official corporate announcement (“提示性公告”) from Hubei Jichuan Pharmaceutical Co., Ltd. regarding the expiry of the first lock-up period of its 2025 employee shareholding plan, detailing share transfers, lock-up schedule, and post-lock-up sale arrangements. This is a disclosure about changes in the company’s capital structure related to its employee share plan, rather than a financial report, management change, earnings release, or other more specific category. It therefore best aligns with “Share Issue/Capital Change (SHA).”
2026-05-27 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.